Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D02FKS
|
||||
| Former ID |
DIB002918
|
||||
| Drug Name |
Selective estrogen receptor degraders
|
||||
| Synonyms |
Selective estrogen receptor degraders (breast cancer); SERDs (breast cancer), Aragon Pharmaceuticals; Selective estrogen receptor degraders (breast cancer), Aragon Pharmaceuticals
|
||||
| Indication | Breast cancer [ICD9: 174, 175; ICD10:C50] | Investigative | [543898] | ||
| Company |
Aragon Pharmaceuticals Inc
|
||||
| Target and Pathway | |||||
| Target(s) | Estrogen receptor | Target Info | Modulator | [543898] | |
| Pathway Interaction Database | Regulation of nuclear SMAD2/3 signaling | ||||
| Signaling events mediated by HDAC Class II | |||||
| Plasma membrane estrogen receptor signaling | |||||
| LKB1 signaling events | |||||
| Regulation of Telomerase | |||||
| ATF-2 transcription factor network | |||||
| AP-1 transcription factor network | |||||
| FOXM1 transcription factor network | |||||
| Validated nuclear estrogen receptor alpha network | |||||
| Signaling mediated by p38-alpha and p38-beta | |||||
| FOXA1 transcription factor network | |||||
| References | |||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Tang and Dr. Zhang.